Heparin recall brings attention to policies
Briefings on The Joint Commission, July 1, 2008
This is an excerpt from a member only article. To read the article in its entirety, please login or subscribe to Briefings on The Joint Commission.
Editor’s note: This feature explores problematic Joint Commission standards with expert advice from BOJ advisors. This month, Elizabeth Di Giacomo-Geffers, RN, MPH, CNAA, BC, a healthcare consultant in Trabuco Canyon, CA, discusses the recent recall of contaminated heparin doses and its effect on medication management standards.
Anticoagulation drugs have been in the spotlight already in the past year, primarily due to National Patient Safety Goal #3E, which targets the safe use of these drugs.
However, a new problem has emerged: Heparin bottles contaminated with oversulfated chondroitin were found at multiple facilities worldwide, from different suppliers.
This is an excerpt from a member only article. To read the article in its entirety, please login or subscribe to Briefings on The Joint Commission.
Comments
0 comments on “Heparin recall brings attention to policies ”
Related Products
Most Popular
- Articles
-
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- HIPAA Q&A: TPO disclosures to a business associate
- Q/A: Coding infusions to correct low potassium levels
- Topic: CMS, OESS post new security compliance review information, checklist
- What does case-mix index mean to you?
- The debate continues: Nurses who reported physician to the Texas Medical Board file federal appeal
- State medical board will hear unprofessional charges against OB-GYN
- Capturing all necessary codes for IUD insertion and removal can be challenging
- QA:Coding multiple initial infusions
- Major mobile operators to support free text alerts
- E-mailed
-
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Q/A: Coding infusions to correct low potassium levels
- Know criteria for coverage when podiatrists use Dermagraft® tissue substitute
- Note: Clarification of reference (non-patient) laboratory testing
- HIPAA Q&A: TPO disclosures to a business associate
- Get the facts on coding for non-biodegradeable drug delivery implants
- Facility E/M Levels, 2009 OPPS
- Do not separately report defibrillation
- Defining 'integral' for self-administered drugs is challenging
- Consider the big picture before querying physicians
- Searched
